Navigation Links
Erbitux in Medical News

Use of Avastin and Erbitux in the Adjuvant Setting and Launches of Emerging Agents Will Drive the Colorectal Cancer Drug Market to $7.8 Billion in 2017

Unmet Need for Efficacious Therapies for Treating Patients With Mutated KRAS Genes Presents Significant Opportunity for Drug Developers, According to a New Report from Decision Resources WALTHAM, Mass., March 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advis...

In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer

Following its Approval, Erbitux Will Earn Gold-Standard Status in 2011, According to a New Report from Decision Resources WALTHAM, Mass., Feb. 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issue...

A New Erbitux Combo Shows Promise in treatment

The US-based ImClone Systems and Bristol-Myers Squibb have announced that a first line phase III study of Erbitux combined with platinum-based //chemotherapy have increased survival chances among cancer patients with recurrent and metastatic squamous cell carcinoma of the head and neck (SCCHN). ...

Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance

...e of 54 percent, primarily due to the inclusion of erbitux revenue as a result of the ImClone acquisition. U....ion of Byetta revenue and $99.7 million of erbitux revenue. Zyprexa In the sec...tta outside the U.S. were $30.6 million. erbitux ((R)) Lilly reports in collaboration revenue...

New Market Research Study Shows Lung Cancer Treatments Differ Significantly by Both Age and Geography

...rolong overall survival. Almost 5,000 NSCLC Patients Monitored Merck KGaA already had presented at last year's ASCO a landmark study for erbitux in combination with standard 1st-line chemotherapy in advanced NSCLC which showed for the first time in 10 years a significant survival benefit in a b...

Chinese Non-Small-Cell Lung Cancer Drug Market Will More Than Double by 2013

...eva (erlotinib) and Jiangsu Simcere's Endostar (endostatin) and the launch of new targeted therapies -- Roche's Avastin (bevacizumab) and Merck KGaA's erbitux (cetuximab) -- are the main driving forces in the Chinese non-small-cell lung cancer market from 2008 to 2013. "In 2008, sales of non-small-cell ...

Sanofi-Aventis' and Roche/Chugai's Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013

... Roche/Chugai's Avastin (bevacizumab) and Merck KGaA/Bristol-Myers Squibb's erbitux (cetuximab) despite their high cost. Growth of these agents and the launch ...illion in 2013. "The increased use of targeted agents like Avastin and erbitux is due to the increasing wealth and urbanization among India's population a...

Lilly Reports Strong First-Quarter 2009 Results

...e of 58 percent, primarily due to the inclusion of erbitux revenue as a result of the ImClone acquisition. U.... Byetta outside the U.S. were $23.7 million. erbitux Lilly reports in collaboration revenue the net royalties received from its erbitux collaboration partners, and in product sales the r...

Targeted Treatments Show Mettle Against Advanced Cancers

...at specific genetic mutations in patients with advanced colorectal cancer could indicate that the tumor will not respond to two monoclonal antibodies, erbitux (cetuximab) and Vectibix (panitumumab). Two studies also to be presented at the meeting focused on the brain tumors known as glioblastomas. One ...

Chinese Colorectal Cancer Drug Market Will More Than Double by 2012

...nt cases, improvement in access to medical care and significantly increased prescribing of targeted therapies. "The increased use of Merck KGaA's erbitux and Jiangsu Simcere's Endostar and the launch of Roche's Avastin will be the strongest drivers of the Chinese colorectal drug market during the next f...
Erbitux in Medical Technology

Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells

Study Presented at 2009 AACR Meeting Highlights Potential Therapeutic Approach to Treat Patients Unresponsive to Erbitux and Vectibix DENVER, April 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treat...

Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX

- ViziLite Plus with TBlue630 - PHOENIX, Sept. 4 /PRNewswire-FirstCall/ -- Zila, Inc.'s (Nasdaq: ZILA ) ViziLite(R) Plus with Tblue630(TM) screening system for early detection of abnormalities which can lead to oral cancer, has been selected to identify pre-cancerous lesio...

Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

NEW YORK--(BUSINESS WIRE)--Apr 4, 2007 - ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that a first line Phase III study of ERBITUX(R) (Cetuximab) combined with platinum-based chemotherapy met the primary endpoint of increasing overall surv...

Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

-- First large, randomized Phase III study of ERBITUX with chemotherapy in recurrent and/or metastatic head and neck cancer meets primary endpoint of improving overall survival -- NEW YORK, April 04, 2007 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated and Bristol-Myers Squibb Company annou...

Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer

NEW YORK, April 10, 2007 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated and Bristol-Myers Squibb Company today announced that a Phase III study of ERBITUX(R) (Cetuximab) plus gemcitabine (a chemotherapy) in patients with locally advanced unresectable or metastatic pancreatic cancer did not...

Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients

- As previously announced, primary endpoint not met; plausibly confounded by survival benefit of post-study treatment with ERBITUX - NEW YORK, April 16, 2007 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated and Bristol-Myers Squibb Company today announced detailed results from the EPIC study...

Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting

NEW YORK--(BUSINESS WIRE)--Jun 5, 2007 - ERBITUX (cetuximab), the first approved IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR) developed and commercialized by ImClone Systems Incorporated, was the focus of nine oral and 46 poster presentations at the recently conclu...

Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer

NEW YORK, July 12, 2007 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated and Bristol-Myers Squibb Company today announced results from an open-label Phase III study of ERBITUX(R) (Cetuximab) plus a taxane and carboplatin in the first-line treatment for metastatic non-small cell lung cancer (...

ARUP Laboratories Applauds FDA's Decision on the Value of KRAS-Mutation Testing in Colorectal Cancer

...elopment, supports the U.S. Food and Drug Administration's (FDA) decision to put KRAS on the label of two targeted drugs, Vectibix (panitumumab) and erbitux (cetuximab). On July 17, 2009, the FDA noted that, "retrospective analyses of metastatic colorectal cancer trials have not shown a treatment benef...

Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

...rior FOLFOX (Oxaliplatin + 5FU + Leucovorin); 63% were previously treated with both FOLFIRI and FOLFOX; 77% received prior Avastin (R) ; and 43% prior erbitux (R) . Prior treatment with single agent capecitabine was excluded. The primary endpoints of this study were to measure 1) Time to Progression (T...

More>>

Erbitux in Biological News

Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics

...atment with Herceptin. In addition, data was recently presented showing the importance of testing for the K-ras gene to assess the clinical benefit of erbitux for metastatic colorectal cancer. Of all the larger integrated healthcare companies, Roche has best executed the synergies of molecular diagnostic...

Two designer drugs hit same lung cancer target, but only one is effective

...er drugs critically influence their effectiveness. erbitux is an effective inhibitor of EGFR signals in color..., MD, and Jänne, all of Dana-Farber. Iressa and erbitux both are designed to squelch the overexpressed, or...ara and his colleagues wanted to determine whether erbitux might be another option for NSCLC patients who car...

FDA Works To Speed The Advent Of New, More Effective Personalized Medicines

...his technology has enabled the development of targeted therapies like Herceptin for metastatic breast cancer, Gleevec for chronic myeloid leukemia and erbitux for metastatic colorectal cancer. "FDA's efforts will bring us one step closer to 'personalizing' medical treatment," explained Janet Woodcock, M.D...
Erbitux in Biological Technology

Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance

... for Erbitux, as well as the later-stage oncology compounds currently in development. -- ERBITUX(R) - In addition to its approved indications, erbitux is also being studied in numerous cancer types, including colorectal, head and neck, non-small cell lung, gastric and esophageal. -- IMC-1121B...

Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors

...al in moving forward the clinical development program for ERBITUX(R) (cetuximab), an oncology drug now approved in colorectal and head & neck cancers. erbitux (cetuximab) is a monoclonal antibody (IgG1 Mab) designed to inhibit the function of a molecular structure expressed on the surface of normal and tumor...

Lilly to Acquire ImClone Systems in $6.5 Billion Transaction

...eater advancements in our proprietary pipeline." erbitux is marketed by ImClone's two partners, Merck KGaA ...istol- Myers Squibb (BMS), and ImClone co-promotes erbitux in North America together with BMS. erbitux is indicated as both a single agent and with chemo...

Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics

...atment with Herceptin. In addition, data was recently presented showing the importance of testing for the K-ras gene to assess the clinical benefit of erbitux for metastatic colorectal cancer. Of all the larger integrated healthcare companies, Roche has best executed the synergies of molecular diagnostic...

ASCO Results: Oncologists Rank Genentech Number One

...ces of data presented at ASCO: -- KRAS status predicts response to first-line cetuximab for metastatic colorectal cancer. -- erbitux (cetuximab) + platinum-based chemotherapy extends overall survival in NSCLC vs. chemotherapy alone. -- Zometa (zoledronic acid) increas...

Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company

...evenue) 273 226 21% 175 144 22% 15% Baraclude 108 45 140% 29 17 71% 59% Oncology erbitux 187 160 17% 185 158 17% N/A Taxol 94 111 (15)% - 4 (100)% N/A Sprycel ...

Oncologists Want to See Significant Improvement in Overall Survival Before Adopting Targeted Polytherapy in a First-Line Setting

...s that would persuade them to add ImClone/Bristol-Myers Squibb/Merck KGaA's erbitux to Genentech/Roche's Avastin and chemotherapy for first-line treatment of a...would require a significant improvement in overall survival in order to add erbitux to Avastin and chemotherapy. On average, oncologists require 24 percent imp...

Biotech 2004: Cautious optimism

... the last two weeks has approved not one but two new cancer drugs coming from biotech companies: Genentechs Avastin and the controversial ImClones erbitux (remember that this is the product and company that did in Marsha Stewart). 2. The hostile announced takeover of the French-German giant Aventis b...
Other Tags
(Date:3/1/2015)... GA (PRWEB) March 01, 2015 ... Evelyn King and Carolyn Roddy to the professional staff ... of Compliance, graduated from The Ohio State University-Mortiz College ... 15 years of experience working with several Fortune 500 ... in the area of corporate benefits. Her experiences range ...
(Date:3/1/2015)... 2015 Theme and plugin developers from ... pack for Final Cut Pro X entitled Transccordion. ... to any FCPX editors project.” Said Christiana Austin, CEO ... tools needed to easily drag and drop their accordion ... many different controls over the parameters of this transition ...
(Date:2/28/2015)... Malaysia (PRWEB) February 28, 2015 The ... all across Malaysia into one platform and gears towards ... , A series of group talks in smaller ... like Nation Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, ... and raise awareness of Malaysian youths. , ...
(Date:2/28/2015)... March 01, 2015 Heart diseases are ... 10 percent of urban adult population and 5 percent ... heart diseases and 20-30 percent of them require specialized ... ailments and coronary vascular diseases (CVD). , A division ... new market research report titled “Indian Coronary Stent Market ...
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 people ... innovative thinking. “The #1 block was lack of ... reports Haman, who created the Thinkubator Innovation Studio in ... that they did not have enough time for innovative ... stimulate innovation. , Solutionman’s monthly “Accelerating Innovation Training” workshops ...
Breaking Medicine News(10 mins):Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
(Date:1/22/2015)... Wis. , Jan. 15, 2015  BellBrook Labs, ... drug discovery, announced the launch of a TR-FRET ... the company,s Transcreener UDP Assay, a high throughput ... The new assay will allow for sensitive detection ...
(Date:1/22/2015)... YORK , Jan. 21, 2015  Analyst Report Issued by ... Card Brands report showed that planet-wide, transactions at merchants on ... while the total number of credit, debit, and prepaid cards ... U.S. were victims of fraudulent card usage in 2012, and ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
Other Contents